AI assistant
Sending…
DEXCOM INC — Director's Dealing 2017
Dec 28, 2017
30198_dirs_2017-12-28_04e1539e-4306-4b0d-a6f0-7d68d3af0355.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2017-12-26
Reporting Person: DOUBLEDAY RICHARD (EVP, Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-26 | Common Stock | S | 1635 | $56.3937 | Disposed | 17245 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 65049 | Direct |
Footnotes
F1: This transaction was executed in multiple trades at prices ranging from $56.16 to $56.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.
More from DEXCOM INC
Regulatory Filings
2026
May 28
Regulatory Filings
2026
May 28
Regulatory Filings
2026
May 14
Interim / Quarterly Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 15
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 17